Clinical trials
Phase 3 Adenocarcinoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
54 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 6 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Recruiting | 10 |
| Terminated | 7 |
| Not yet recruiting | 5 |
| Active, not recruiting | 5 |
| Unknown status | 4 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Astellas Pharma Global Development, Inc. | 4 |
| UNICANCER | 3 |
| AstraZeneca | 2 |
| Australasian Gastro-Intestinal Trials Group | 2 |
| Boehringer Ingelheim | 2 |
| Eli Lilly and Company | 2 |
| Abbott | 1 |
| Akeso | 1 |
| Ariad Pharmaceuticals | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adenocarcinoma | 54 |
| Neoplasms | 11 |
| Stomach Neoplasms | 11 |
| Carcinoma | 8 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Pancreatic Neoplasms | 6 |
| Digestive System Neoplasms | 5 |
| Neoplasms by Site | 5 |
| Carcinoma, Squamous Cell | 4 |
| Digestive System Diseases | 4 |
Trials
Showing 51 to 54 of 54. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.